Work Here?
Overview
YPrime provides software and services for clinical trials, focusing on electronic Clinical Outcome Assessments (eCOA) and Interactive Response Technology (IRT). Their eCOA tools collect patient data electronically, replacing paper methods, while IRT systems manage randomization and drug supply to keep trials running smoothly. The company licenses its software to pharmaceutical and biotechnology clients and offers ongoing support, customization, and consulting to design and implement trials. What sets YPrime apart is the combination of integrated eCOA and IRT solutions with services that tailor implementations to clients’ needs, aiming to improve data quality, reduce trial costs, and speed up getting new treatments to market. The overall goal is to streamline clinical trials and help pharma and biotech companies run more efficient, compliant studies through technology and expert services.
About YPrime
Industries
Data & Analytics
Consulting
Enterprise Software
Healthcare
Company Size
201-500
Company Stage
Seed
Total Funding
$10M
Headquarters
Malvern, Pennsylvania
Founded
2006
Get referred to YPrime
See people who can refer or advise you
Simplify's Take
What believers are saying
- April 2026 product launches show active roadmap execution and faster configuration cycles.
- YPrime serves 100-plus countries and 250-plus languages, supporting multinational trial demand.
- September 2025 Everest leadership reinforces sponsor trust for large pharma and CRO renewals.
What critics are saying
- Clario, Medidata, and Signant Health already match YPrime’s eCOA breadth and scale.
- AI calculation and oversight features commoditize quickly, forcing price pressure by 2027.
- No public funding or profitability disclosures since 2022 keep YPrime financially opaque.
What makes YPrime unique
- YPrime remains an Everest Group 2025 eCOA Leader alongside Clario and Medidata.
- April 2026 Participant Hub centralizes study tasks inside YPrime’s eCOA application.
- April 2026 AI Calculation Engine automates logic configuration across YPrime’s eCOA lifecycle.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$10M
Above
Industry Average
Funded Over
0 Rounds
Benefits
Unlimited Paid Time Off
401(k) Company Match
401(k) Retirement Plan
Flexible Work Hours
Professional Development Budget
Company News
IRT UAT for clinical trials: faster go-lives through smarter validation. A YPrime Blog By: Ryan Ridge Vice President, IRT Operations YPrime Clinical trial startup timelines are accelerating, but the operational demands behind successful go-lives have only grown more complex. For sponsors implementing IRT, RTSM, and eCOA systems, User Acceptance Testing (UAT) often becomes the defining factor between a predictable go-live and delayed study startup. In many cases, the technology is not the issue. Execution is. During a recent IRT implementation, YPrime faced a significant timeline acceleration after study leadership moved the expected go-live date forward by approximately two months. While system configuration and implementation remained on track, the compressed timeline introduced additional pressure around validation, coordination, operational readiness, and inspection-ready execution. To support the accelerated timeline, YPrime partnered with Clinical Supply Consulting (CSC) to execute a focused, risk-based UAT strategy designed to maintain validation rigor, audit readiness, operational oversight, and study integrity without delaying startup. The result was a streamlined clinical trial UAT approach that accelerated validation while preserving the rigor and oversight required for complex IRT and eCOA implementations. The sponsor's study configuration, workflows, and implementation plan were progressing successfully until leadership accelerated the expected go-live timeline by approximately two months. The technology itself was ready, but traditional UAT execution models were not built to support the compressed schedule. Like many IRT and eCOA implementations, the greatest risks during clinical trial UAT were operational rather than technical: limited SME availability, fragmented review cycles, slow script approvals, delayed issue resolution and disconnected testing ownership. In complex IRT and eCOA studies, these delays can create downstream operational impact across supply management, randomization readiness, participant workflows, integrations, and data collection continuity. UAT frequently becomes the least flexible phase of the implementation timeline because execution depends heavily on coordination across multiple stakeholders and systems. Rather than reducing validation requirements, the teams focused on a different question: How can IRT UAT be executed more efficiently without compromising quality, compliance, or inspection readiness? To support the accelerated timeline, YPrime led a redesigned UAT execution strategy centered around speed, accountability, and operational focus. CSC provided dedicated UAT support and execution expertise to help streamline coordination, testing workflows, and issue resolution during validation. Instead of relying on fragmented ownership, disconnected testing cycles, and delayed approvals, the teams centralized execution under a dedicated clinical trial UAT structure designed to support faster collaboration, focused validation, audit-ready documentation, and accelerated IRT go-live readiness. Internal AI-supported workflows also helped streamline execution and improve operational efficiency during validation. The strategy included: Dedicated UAT support with clear ownership and accountability, real-time collaboration and issue resolution, risk-based workflow prioritization, focused testing of high-impact operational scenarios, validation centered on real-world study execution, streamlined communication and faster decision-making, and audit-ready documentation practices. Rather than measuring success through documentation volume alone, the teams prioritized meaningful validation of workflows most likely to impact participant experience, randomization accuracy, supply coordination, integrations, and clinical trial operations. Questions were addressed immediately through direct collaboration instead of lengthy review cycles. Feedback loops shortened. Execution became coordinated, focused, and significantly more efficient. The revised approach enabled the sponsor to complete a concentrated one-day UAT effort while maintaining validation rigor, operational oversight, and inspection readiness. Most importantly, the accelerated timeline did not come from eliminating oversight or bypassing quality controls. It came from improving operational alignment, execution discipline, communication, and validation focus. The project reinforced several important realities about modern IRT and eCOA UAT execution: - Faster validation does not mean lower quality - Risk-based UAT can improve efficiency without increasing risk - Operational alignment is often the biggest factor in successful go-lives - Dedicated UAT expertise can reduce execution friction during compressed timelines - Real-time collaboration accelerates issue resolution and operational decision-making - Focused validation improves confidence in study readiness - Inspection-ready execution requires both technology and operational discipline For sponsors implementing IRT and eCOA platforms, these distinctions matter. As clinical trials become more complex and globally distributed, organizations need validation strategies capable of supporting both accelerated timelines and regulatory expectations. IRT and eCOA UAT remain critical components of clinical trial system validation because they demonstrate that clinical technologies perform correctly under real-world study conditions before study go-live. Regulatory agencies expect sponsors to show traceability, process control, operational accountability, and confidence across clinical technologies prior to launch. For IRT and eCOA programs specifically, effective UAT helps validate: - Participant workflows - Randomization logic - Visit schedules - Drug supply coordination - System integrations - User permissions - Calculation accuracy - Data integrity and traceability - Site workflows and operational readiness - Audit-ready documentation practices The goal is not simply to complete testing documentation. The goal is to establish confidence that systems will perform reliably during live clinical trial execution. This case study highlights an important shift happening across clinical trial technology implementations. The future of faster IRT and eCOA go-lives will not come from reducing validation requirements. It will come from improving how validation is executed. As IRT, RTSM, and eCOA studies become more complex, sponsors need modern UAT strategies capable of supporting accelerated study startup timelines without compromising operational oversight, inspection readiness, or data integrity. Risk-based UAT execution, dedicated validation support, and stronger operational alignment are becoming essential components of successful clinical trial technology implementations. Sponsors that modernize UAT through risk-based testing, dedicated operational support, streamlined collaboration, and AI-enhanced execution will be better positioned to accelerate timelines while maintaining compliance and study quality. For clinical trial teams facing compressed startup timelines, smarter IRT UAT execution may be one of the most important opportunities to improve operational performance without increasing operational or regulatory risk. With decades of combined IRT and eCOA expertise, YPrime helps sponsors and CROs with eClinical technology with partnerships that support UAT. Frequently asked questions. What is IRT in clinical trials? IRT, or Interactive Response Technology refers to the system used to manage patient randomization, drug supply, cohort assignments, and operational logistics - ensuring accurate execution in large, adaptive, and global studies. Why is IRT critical for study execution? IRT is critical for study execution because it enables sponsors to manage complex protocols, global supply chains, and real-time data integrity while maintaining regulatory compliance and operational control across thousands of patients and sites. How does IRT support adaptive trial designs? IRT supports adaptive trial designs by enabling seamless protocol amendments, flexible cohort configurations, and dosing strategy changes, without interrupting ongoing study operations or requiring lengthy revalidations. What is IRT UAT in clinical trials? IRT UAT is the process used to validate that Interactive Response Technology (IRT) or RTSM systems function correctly before clinical trial go-live. UAT confirms randomization logic, drug supply workflows, visit schedules, integrations, user permissions, and operational readiness under real-world study conditions. Why does UAT delay IRT and eCOA go-lives? UAT delays are often caused by fragmented execution, limited SME availability, disconnected ownership, slow feedback cycles, and inefficient collaboration processes rather than the technology itself. Ready to rethink your clinical trial strategy? Check out what its experts have to say. about trial design, data capture, operational efficiencies, and, ultimately, how to solve with certainty in clinical research.
YPrime, a clinical trial technology company, has launched an AI-powered Calculation Engine within its eCOA platform to standardise calculation logic configuration and execution throughout trial lifecycles. The system enables study teams to generate calculation logic conversationally using natural language, which is then translated into structured, traceable calculation models. The engine automates questionnaire scoring, eligibility criteria, compliance tracking and endpoint derivation, reducing manual programming and validation cycles. It executes configured logic automatically as participant data is collected, ensuring accurate scoring throughout studies. The launch follows YPrime's AI-powered migration capabilities and reflects the company's strategy to embed AI directly into study design and execution. The Calculation Engine is now available as part of YPrime's eCOA platform, which serves pharmaceutical and biotech companies across 100-plus countries.
YPrime wins two Clinical Trials Arena Excellence Awards for innovation in AI and sustainable eCOA practices. MALVERN, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) - YPrime, a proven leader in clinical trial technology, today announced it has received two distinctions in the 2025 Clinical Trials Arena Excellence Awards: Innovation for AI in Clinical Trials and Environmental Excellence for Sustainable Trials. Powered by GlobalData's independent research, the Clinical Trials Arena Excellence Awards recognize organizations advancing meaningful progress across the clinical research ecosystem. "We have embedded environmental responsibility, ethics, and human-centered values into our business strategy because clinical innovation and sustainable..." "AI is helping us remove friction from one of the most complex parts of global eCOA delivery," "By automating the most technical steps and preserving linguist expertise where it matters most, we can help sponsors activate studies faster, reach more..." "At YPrime, doing good and doing well are not competing priorities - they are mutually reinforcing," "We have embedded environmental responsibility, ethics, and human-centered values into our business strategy because clinical innovation and sustainable..." "AI is helping us remove friction from one of the most complex parts of global eCOA delivery," "By automating the most technical steps and preserving linguist expertise where it matters most, we can help sponsors activate studies faster, reach more..." "At YPrime, doing good and doing well are not competing priorities - they are mutually reinforcing," "We have embedded environmental responsibility, ethics, and human-centered values into our business strategy because clinical innovation and sustainable..." YPrime earned recognition for two standout initiatives: its pioneering application of artificial intelligence (AI) to accelerate eCOA localization, and its company-wide efforts to embed sustainability into clinical trial workflows - from digital-first product design to measurable reductions in environmental footprint. The honors reflect YPrime's continued commitment to advancing trial efficiency, data quality, and global participation through responsible, future-focused technology. AI Innovation: Solving a Persistent Bottleneck in eCOA Localization The Innovation Award recognizes YPrime's work applying domain-specific AI to one of the most overlooked drivers of delay in global clinical trials, the migration of translated Clinical Outcome Assessments (COAs) into eCOA platforms. Traditionally a manual, error-prone step, migration requires aligning complex file structures, HTML tag logic, and linguistic formatting across dozens of languages - often prompting multiple rounds of reproofing and introducing costly delays to study startup. YPrime reframed the challenge by automating the migration step itself. Its AI migration engine is trained on YPrime's proprietary file structures and tagging logic, enabling precise alignment of text, tags, and formatting before human review. In a comparative analysis of 15 studies across 11 languages, YPrime's AI-enabled workflow delivered measurable gains, including: * 74% fewer migration errors * 60% fewer screen reports requiring rework * 67% faster localization review cycles * 0 new error types introduced by AI "AI is helping us remove friction from one of the most complex parts of global eCOA delivery," said Jonathan Norman, Director of Localization & Scale Management at YPrime. "By automating the most technical steps and preserving linguist expertise where it matters most, we can help sponsors activate studies faster, reach more languages, and collect cleaner, more representative data." Environmental Leadership: Sustainable Trials by Design YPrime also received the Clinical Trials Arena Environmental Excellence Award for embedding sustainability into clinical trial execution. The company's digital-first platforms - eCOA, IRT, and eConsent - replace paper-based processes, reduce site-dependent workflows, and minimize shipments and travel. Over multiple years, these product decisions, coupled with operational changes, have driven measurable progress: * 87% reduction in printed trial documents over three years * 100% reuse or recycling of clinical trial devices through circularity programs * Zero Scope 1 emissions achieved, with reductions across Scope 2 and 3 * Sustainability integrated into supplier oversight, including a Supplier Code of Conduct * EcoVadis Bronze and CDP "B" ratings achieved in 2024 "At YPrime, doing good and doing well are not competing priorities - they are mutually reinforcing," said Ian Lennox, CEO of YPrime. "We have embedded environmental responsibility, ethics, and human-centered values into our business strategy because clinical innovation and sustainable practices must go hand in hand. These awards recognize the work of our teams and partners who are helping build a more responsible, inclusive future for clinical research." These dual awards show YPrime's leadership, following recent launches such as Advanced eCOA Oversight, Automated Data Change Forms (DCF), connected device integrations, and YPrime's industry-leading approach to AI-supported eCOA localization. YPrime was also named a Leader in the Everest Group 2025 eCOA PEAK Matrix(R) Assessment and recognized as a Trailblazer in Patient Engagement. To learn more about YPrime's award-winning innovations and global clinical technology solutions, visit www.yprime.com, or Clinical Trials Arena. About YPrime YPrime simplifies clinical trials with eCOA, IRT, and eConsent solutions that combine speed, flexibility, and quality. The YPrime eCOA platform enhances participant compliance with an intuitive app and easy-to-use design, streamlines site workflows through a powerful eCOA portal, integrates seamlessly with connected devices, and supports sponsors with dashboards for better decision-making. AI-supported eCOA localization accelerates globalization, while pre-validated and configurable eCOA and IRT deliver faster study startup with quality metrics above industry standards. Trusted by top pharma leaders and emerging biotech companies alike, YPrime blends deep industry expertise and innovation to deliver reliable solutions. With nearly two decades of proven success, solutions in 250+ languages, and support in 100+ countries, YPrime is your partner to solve clinical research challenges with certainty. Visit www.yprime.com or email [email protected]. About GlobalData GlobalData Plc (AIM: DATA) is a leading data, insights, and analytics platform that delivers trusted proprietary insights and tailored intelligence solutions for the world's largest industries. The company's mission is to help clients decode the future, make better decisions, and reach more customers. By combining proprietary data with human expertise and powerful AI, GlobalData provides next-generation intelligence through one connected platform. For more information, visit https://www.globaldata.com. Media Contact Grazia Mohren Senior Vice President, Marketing, YPrime [email protected]
YPrime launches Advanced eCOA Oversight to strengthen investigator accountability and participant safety. MALVERN, PA - October 29, 2025 - YPrime, a proven leader in clinical trial technology, today announced the launch of its Advanced eCOA Oversight functionality - a key enhancement to its eCOA platform designed to simplify and strengthen how Principal Investigators (PIs) review and acknowledge participant data. Recent updates from the EMA Guideline on Computerized Systems[1] and ICH E6(R3)[2] emphasize that investigator oversight must be documented, attributable, and demonstrable, including electronic review and endorsement of study data at predetermined milestones. These frameworks reinforce the investigator's responsibility to maintain data integrity, ensure participant safety, and confirm the accuracy and completeness of data submitted to sponsors. YPrime's Advanced eCOA Oversight addresses these evolving regulatory expectations by embedding a compliant, auditable signature workflow directly into the eCOA platform. * Attributable Signatures: Each electronic sign-off is securely tied to the individual investigator, maintaining 21 CFR Part 11 compliance. * Re-Signature Capability: When data is changed after prior sign-off, the system automatically prompts the PI to review and re-sign, ensuring data continuity and traceability. * Demonstrable Oversight: Investigators can review and acknowledge participant data at their convenience within the eCOA platform. * Audit-Ready Reporting: Oversight reports capture electronic data review, signature history, timestamps, and data changes for inspection or submission. "YPrime's Advanced eCOA Oversight represents the next evolution of our eCOA platform - giving investigators and sponsors greater visibility, faster access to verified data, and a more efficient path to study delivery," said Ian Lennox, Chief Executive Officer at YPrime. "It's a strong example of how we continue to anticipate what sites and regulators need, while enabling trials to run with greater confidence and control." By digitizing the PI acknowledgment process, YPrime eliminates the need for manual print-and-sign workflows that have long burdened clinical research sites. Investigators can now fulfill their regulatory responsibilities within a single, secure system that records every review and endorsement in real time. "Regulatory agencies are making it clear that investigator oversight must be traceable, attributable, and electronic," said Aubrey Verna, Senior Product Director of eCOA at YPrime. "This feature ensures those expectations are met, streamlining oversight while maintaining the highest levels of compliance and data integrity." This launch extends YPrime's commitment to innovation that accelerates compliance and operational excellence, while improving the experience for participants and sites. Recent eCOA enhancements - including YPrime's AI-powered eCOA localization, Automated Data Change Forms (DCF), and glucometer integrations - underscore the company's mission to advance science and health by simplifying clinical trials, empowering sponsors to launch faster, with high quality data, and stronger participant engagement. YPrime was recently named a Leader in Everest Group's 2025 eCOA PEAK Matrix(R) Assessment, recognizing the company's proven ability to deliver scalable, high-quality eCOA solutions that meet the speed and complexity of today's global clinical trials. This latest release builds on that leadership, demonstrating YPrime's continued investment in clinical trial innovation. YPrime was also previously recognized as a Trailblazer in Patient Engagement by Everest Group in 2024, underscoring its commitment to creating digital tools that make clinical trials more intuitive, patient-centered, and efficient. About YPrime YPrime simplifies clinical trials with eCOA, IRT, and eConsent solutions that combine speed, flexibility, and quality. The YPrime eCOA platform enhances participant compliance with an intuitive app and easy-to-use design, streamlines site workflows through a powerful eCOA portal, integrates seamlessly with connected devices, and supports sponsors with dashboards for better decision-making. AI-supported eCOA localization accelerates globalization, while pre-validated and configurable eCOA and IRT deliver faster study startup with quality metrics above industry standards. Trusted by top pharma leaders and emerging biotech companies alike, YPrime blends deep industry expertise and innovation to deliver reliable solutions. With nearly two decades of proven success, solutions in 250+ languages, and support in 100+ countries, YPrime is your partner to solve clinical research challenges with certainty. Visit www.yprime.com or email [email protected]. Media Contact Grazia Mohren Senior Vice President, Marketing, YPrime [email protected]
MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) - YPrime, a proven leader in clinical trial technology, today announced it has been recognized as a Leader in the Everest Group's Life Sciences Electronic Clinical Outcome Assessment (eCOA) Products PEAK Matrix(R) Assessment 2025.
There are no jobs for YPrime right now.
Find jobs on Simplify and start your career today
About YPrime
Industries
Data & Analytics
Consulting
Enterprise Software
Healthcare
Company Size
201-500
Company Stage
Seed
Total Funding
$10M
Headquarters
Malvern, Pennsylvania
Founded
2006
There are no jobs for YPrime right now.
Find jobs on Simplify and start your career today